Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study
The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treat...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2018-12, Vol.97 (49), p.e13412-e13412 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e13412 |
|---|---|
| container_issue | 49 |
| container_start_page | e13412 |
| container_title | Medicine (Baltimore) |
| container_volume | 97 |
| creator | Domachevsky, Liran Kashtan, Hanoch Brenner, Baruch Nidam, Meital Morgenstern, Sara Kundel, Yulia Groshar, David Bernstine, Hanna |
| description | The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42%, 50% and 60% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer. |
| doi_str_mv | 10.1097/MD.0000000000013412 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6310504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157649233</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3554-a4a40348eaade71200636daa8bf57f71cbf2bbabeb557b9cd52223b3209d0ad33</originalsourceid><addsrcrecordid>eNpdkUtv1DAUhS0EokPhFyAhL9mk9TOesEAqM50WqRUshrV149xMUjJxsJ2pZs8PJ9Mp5eGNJfs759rnEPKWszPOCnN-uzxjfxaXiotnZMa1zDNd5Oo5mTEmdGYKo07IqxjvDpAR6iU5kUwrpXgxIz8_QcSu7ZHy-SpbLa_o18v1-WJNIdIhYNW65AP1NU0N0gFS4zu_aR10NGAcfB-RJk979FDdjTvo0wEMMOxp21OMfmhggxPtoHcYPtCLSZeCjwO61O6QxjRW-9fkRQ1dxDeP-yn5trpcL66zmy9XnxcXN5mTWqsMFCgm1RwBKjRcMJbLvAKYl7U2teGurEVZQoml1qYsXKWFELKUghUVg0rKU_Lx6DuM5RYrh30K0NkhtFsIe-uhtf_e9G1jN35nc8mZZmoyeP9oEPyPEWOy2zY67DqYEhijFVybXBVCHmbJI-qm38aA9dMYzuyhP3u7tP_3N6ne_f3CJ83vwiZAHYF73yUM8Xs33mOwzZRxah78tClEJhifTwEZlh1OlPwFpXSnvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157649233</pqid></control><display><type>article</type><title>Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study</title><source>IngentaConnect Backfiles</source><source>MEDLINE</source><source>PubMed Central(OpenAccess)</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Wolters Kluwer Open Access</source><creator>Domachevsky, Liran ; Kashtan, Hanoch ; Brenner, Baruch ; Nidam, Meital ; Morgenstern, Sara ; Kundel, Yulia ; Groshar, David ; Bernstine, Hanna</creator><creatorcontrib>Domachevsky, Liran ; Kashtan, Hanoch ; Brenner, Baruch ; Nidam, Meital ; Morgenstern, Sara ; Kundel, Yulia ; Groshar, David ; Bernstine, Hanna</creatorcontrib><description>The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42%, 50% and 60% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000013412</identifier><identifier>PMID: 30544419</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Aged ; Chemoradiotherapy ; Esophageal Neoplasms - diagnostic imaging ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Female ; Fluorodeoxyglucose F18 ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Observational Study ; Positron Emission Tomography Computed Tomography ; Prognosis ; Radiopharmaceuticals ; Retrospective Studies</subject><ispartof>Medicine (Baltimore), 2018-12, Vol.97 (49), p.e13412-e13412</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3554-a4a40348eaade71200636daa8bf57f71cbf2bbabeb557b9cd52223b3209d0ad33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310504/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310504/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30544419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Domachevsky, Liran</creatorcontrib><creatorcontrib>Kashtan, Hanoch</creatorcontrib><creatorcontrib>Brenner, Baruch</creatorcontrib><creatorcontrib>Nidam, Meital</creatorcontrib><creatorcontrib>Morgenstern, Sara</creatorcontrib><creatorcontrib>Kundel, Yulia</creatorcontrib><creatorcontrib>Groshar, David</creatorcontrib><creatorcontrib>Bernstine, Hanna</creatorcontrib><title>Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42%, 50% and 60% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.</description><subject>Aged</subject><subject>Chemoradiotherapy</subject><subject>Esophageal Neoplasms - diagnostic imaging</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Observational Study</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1DAUhS0EokPhFyAhL9mk9TOesEAqM50WqRUshrV149xMUjJxsJ2pZs8PJ9Mp5eGNJfs759rnEPKWszPOCnN-uzxjfxaXiotnZMa1zDNd5Oo5mTEmdGYKo07IqxjvDpAR6iU5kUwrpXgxIz8_QcSu7ZHy-SpbLa_o18v1-WJNIdIhYNW65AP1NU0N0gFS4zu_aR10NGAcfB-RJk979FDdjTvo0wEMMOxp21OMfmhggxPtoHcYPtCLSZeCjwO61O6QxjRW-9fkRQ1dxDeP-yn5trpcL66zmy9XnxcXN5mTWqsMFCgm1RwBKjRcMJbLvAKYl7U2teGurEVZQoml1qYsXKWFELKUghUVg0rKU_Lx6DuM5RYrh30K0NkhtFsIe-uhtf_e9G1jN35nc8mZZmoyeP9oEPyPEWOy2zY67DqYEhijFVybXBVCHmbJI-qm38aA9dMYzuyhP3u7tP_3N6ne_f3CJ83vwiZAHYF73yUM8Xs33mOwzZRxah78tClEJhifTwEZlh1OlPwFpXSnvg</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Domachevsky, Liran</creator><creator>Kashtan, Hanoch</creator><creator>Brenner, Baruch</creator><creator>Nidam, Meital</creator><creator>Morgenstern, Sara</creator><creator>Kundel, Yulia</creator><creator>Groshar, David</creator><creator>Bernstine, Hanna</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181201</creationdate><title>Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study</title><author>Domachevsky, Liran ; Kashtan, Hanoch ; Brenner, Baruch ; Nidam, Meital ; Morgenstern, Sara ; Kundel, Yulia ; Groshar, David ; Bernstine, Hanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3554-a4a40348eaade71200636daa8bf57f71cbf2bbabeb557b9cd52223b3209d0ad33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Chemoradiotherapy</topic><topic>Esophageal Neoplasms - diagnostic imaging</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Observational Study</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domachevsky, Liran</creatorcontrib><creatorcontrib>Kashtan, Hanoch</creatorcontrib><creatorcontrib>Brenner, Baruch</creatorcontrib><creatorcontrib>Nidam, Meital</creatorcontrib><creatorcontrib>Morgenstern, Sara</creatorcontrib><creatorcontrib>Kundel, Yulia</creatorcontrib><creatorcontrib>Groshar, David</creatorcontrib><creatorcontrib>Bernstine, Hanna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domachevsky, Liran</au><au>Kashtan, Hanoch</au><au>Brenner, Baruch</au><au>Nidam, Meital</au><au>Morgenstern, Sara</au><au>Kundel, Yulia</au><au>Groshar, David</au><au>Bernstine, Hanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>97</volume><issue>49</issue><spage>e13412</spage><epage>e13412</epage><pages>e13412-e13412</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42%, 50% and 60% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30544419</pmid><doi>10.1097/MD.0000000000013412</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2018-12, Vol.97 (49), p.e13412-e13412 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6310504 |
| source | IngentaConnect Backfiles; MEDLINE; PubMed Central(OpenAccess); DOAJ Directory of Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library; Wolters Kluwer Open Access |
| subjects | Aged Chemoradiotherapy Esophageal Neoplasms - diagnostic imaging Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Female Fluorodeoxyglucose F18 Humans Male Middle Aged Neoadjuvant Therapy Observational Study Positron Emission Tomography Computed Tomography Prognosis Radiopharmaceuticals Retrospective Studies |
| title | Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A25%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baseline%2018F-FDG%20PET/CT%20as%20predictor%20of%20the%20pathological%20response%20to%20neoadjuvant%20therapy%20in%20esophageal%20cancer:%20A%20retrospective%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Domachevsky,%20Liran&rft.date=2018-12-01&rft.volume=97&rft.issue=49&rft.spage=e13412&rft.epage=e13412&rft.pages=e13412-e13412&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000013412&rft_dat=%3Cproquest_pubme%3E2157649233%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157649233&rft_id=info:pmid/30544419&rfr_iscdi=true |